Home Cart Sign in  
Chemical Structure| 1809336-39-7 Chemical Structure| 1809336-39-7

Structure of Valemetostat
CAS No.: 1809336-39-7

Chemical Structure| 1809336-39-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Valemetostat is an antineoplastic agent.

Synonyms: DS-3201; (R)-OR-S2; DS-3201b

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Valemetostat

CAS No. :1809336-39-7
Formula : C26H34ClN3O4
M.W : 488.02
SMILES Code : O=C(C1=CC(Cl)=C(O[C@](C)([C@H]2CC[C@H](N(C)C)CC2)O3)C3=C1C)NCC4=C(C)C=C(C)NC4=O
Synonyms :
DS-3201; (R)-OR-S2; DS-3201b
MDL No. :MFCD31692361

Safety of Valemetostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Valemetostat

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BCBL-1 cells 1 µM 24 hours To evaluate the activation of the KSHV lytic cycle by DS, results showed DS induced the expression of KbZIP and p64 PMC11437442
BC3 cells 1 µM 24 hours To evaluate the activation of the KSHV lytic cycle by DS, results showed DS induced the expression of KbZIP and p64 PMC11437442
TCS627 cells 0.02 µM, 0.2 µM, 2 µM 48 hours To evaluate the growth inhibitory potential of EZH1/2 inhibitor valemetostat on TCS627 cells, showing only 25% growth reduction at 2 µM concentration. PMC10778008
ATL cell lines (TL-Om1, ATN-1) 10 nM to 100 nM 2 months Establish resistant cell models and evaluate resistance mechanisms PMC10917674
PBMCs 0.1 μM and 1 μM 7 days To evaluate the inhibitory effect of Valemetostat on spontaneous proliferation of PBMCs from HAM patients. Results showed that Valemetostat significantly inhibited the spontaneous proliferation of PBMCs. PMC10291084
HCT-5 cells 1 μM 21 days To evaluate the effect of Valemetostat on cell viability and apoptosis in HTLV-1-infected cell lines. Results showed that Valemetostat significantly reduced the viability of HCT-5 cells and induced early apoptosis. PMC10291084
HCT-4 cells 1 μM 21 days To evaluate the effect of Valemetostat on cell viability and apoptosis in HTLV-1-infected cell lines. Results showed that Valemetostat significantly reduced the viability of HCT-4 cells and induced early apoptosis. PMC10291084
BCBL-1 cells 1 µM or 2 µM 48 hours To evaluate the effect of Valemetostat on PEL cell survival and STAT3 activation. Results showed that Valemetostat slightly reduced PEL cell survival and slightly affected STAT3 phosphorylation and c-Myc expression. PMC10968859
BC3 cells 1 µM or 2 µM 48 hours To evaluate the effect of Valemetostat on PEL cell survival and STAT3 activation. Results showed that Valemetostat slightly reduced PEL cell survival and slightly affected STAT3 phosphorylation and c-Myc expression. PMC10968859

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCIDbg mice MCL patient-derived xenograft model Oral 200 mg/kg Twice daily for 3 weeks OR-S1 significantly inhibited MCL tumor growth, whereas ibrutinib did not. PMC8177787

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04276662 Hepatic Impairment PHASE1 COMPLETED 2021-02-23 Clinical Pharmacology of Miami... More >>, LLC, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Worldwide Clinical Trials, San Antonio, Texas, 78217, United States Less <<
NCT03110354 Leukemia, Myeloid, Acute|Leuke... More >>mia, Lymphocytic, Acute Less << PHASE1 TERMINATED 2021-03-09 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Duke University, Durham, North Carolina, 27710, United States|Vanderbilt University, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.20mL

10.25mL

2.05mL

1.02mL

20.49mL

4.10mL

2.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories